Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 13 Best Low Risk High Growth Stocks to Buy. Analysts are ...

Corcept Therapeutics CORT announced that it has submitted a new drug application (NDA) to the FDA seeking approval for its ...

Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer Provided by Business Wire Jul 14, 2025, 5:00:00 AM ...

Corcept Submits NDA For Relacorilant To Treat Platinum-Resistant Ovarian Cancer July 14, 2025 — 01:03 pm EDT Written by RTTNews.com for RTTNews -> ...

Corcept is studying relacorilant in a variety of serious disorders in addition to ovarian cancer, including endogenous hypercortisolism (Cushing’s syndrome) and prostate cancer.

By Colin Kellaher Corcept Therapeutics has filed for U.S. Food and Drug Administration approval of its relacorilant drug candidate for the treatment of patients with platinum-resistant ovarian cancer.

In a recent paper published in Nature, researchers at the University of Chicago discovered how to block nicotinamide N-methyl ...